ICG-366

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameICG-366
Drug Alias NameICG366ICG-366
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsT lymphoblastic lymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSonghe Immunobiological Medical (Shenzhen) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSonghe Immunobiological Medical (Shenzhen) Co Ltd
Inactive CompaniesN/A
Active IndicationsT lymphoblastic lymphomaLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A